"Including evidence-based decision-making in the healthcare coverage process would ensure that use of new therapy and technology is tied to evidence of clinical benefit, resulting in a value-based health care system."
— Rita Redberg, MD. Health Affairs, February 2007
In the News
An abstract entitled “Clinical utility of gene-expression profiling for tumor site origin” has been accepted for publication for the 2011 ASCO Annual Meeting, reporting results of a study by Cedar’s John Hornberger, Hialy Gutierrez, and Richard Hornberger, together with David Henner and Shawn Becker of Pathwork Diagnostics Inc., Gauri Varadhachary of MD Anderson Cancer Center, Scott Nystrom of Tufts Medical Center, Mahul Amin of Cedars Sinai, and Michael Walker of Stanford University.
An independent collaboration between John Hornberger and Rebecca Chien, Cedar Associates; and Louis Hochheiser and Katie Krebs, Humana Inc; on real-world economic implications of a breast cancer molecular risk-stratifier will be presented at the 16th Annual ISPOR meeting on Wednesday, May 25th 2011.
Cedar’s John Hornberger, Ashwini Shewade and Hialy Gutierrez will be presenting a poster at ISPOR’s 2011 annual meeting in Baltimore, Maryland, on assessing coverage decisions made by publicly funded health care programs in low- and middle-income countries, part of a larger initiative sponsored by the Rockefeller Foundation to transform health systems.
J. Hornberger. et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma. 2008;49 ( 2 ):227-36, has recently been included in the Tufts Medical Center Cost-Effectiveness Analysis (CEA) registry (www.cearegistry.org).
The CEA Registry summarizes and reviews original, English-language cost-utility analysis articles published in the peer reviewed literature. Studies are identified through a search of the Medline database using predetermined search terms.
Cedar Associates LLC provides life sciences organizations and companies with scientifically reliable and credible evidence on clinical outcomes and economics of services and technologies. We use state-of-the-art analytical techniques and seek to present our findings in a manner that is readily understood by a diverse audience, such as physicians, patients, managers, and third-party payers and decision-makers.
We have close collaborations with numerous international renowned experts at local, regional and national institutions (e.g., Stanford University, UC Berkeley, California State University East Bay, Sutter Health, Veterans’ Affairs Hospitals). These collaborations not only expand the scope of state-of-the-art expertise on projects, but increase our capacity to readily staff projects.